NRx Pharmaceuticals, Inc. (NRXP)
Nasdaq · Healthcare · Biotechnology
$2.87−1.20%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $124M
- 52-week range
- $1.62 – $5.06
- 52-week change
- −20.84%
- EPS (trailing)
- −$0.58
- Analyst rating
- 1.0 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $1.2M
- Net income
- −$28.6M
- Operating margin
- −1324.4%
From the company’s annual report on SEC EDGAR.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc.
Headquarters: Wilmington, United States · 29 employees · nrxpharma.com